Multistep extracorporeal support strategy for community-acquired pneumonia complicated by sepsis and multiple organ failure (A clinical case)
https://doi.org/10.34215/1609-1175-2026-2-86-89
Abstract
This article presents a clinical case report of a 49-year-old male patient with severe community-acquired bilateral polysegmental pneumonia, complicated by sepsis and multiple organ failure including acute kidney injury (AKI) with oliguria, severe hyperbilirubinemia, and thrombocytopenia with suspected thrombotic microangiopathy (TMA). Objective: To demonstrate strategies for the differential diagnosis of TMA in severe pneumonia and the sequential use of extracorporeal therapies (ECT). Severity was assessed using the SOFA score. Renal replacement therapy (RRT) was performed as continuous veno-venous hemofiltration (CVVH) in three intervals. Therapeutic plasma exchange (TPE) consisted of two sessions, each involving two volumes of circulating plasma. Prior to ECT, a blood sample was collected to measure ADAMTS13 activity. In the context of complex therapy involving CVVH and TPE, the SOFA score decreased from 12 to 7 points. Additionally, the platelet count increased from 30 × 10⁹/L to 187 × 10⁹/L, bilirubin levels decreased from 559.6 to 16.6 μmol/L, and diuresis was restored. However, ADAMTS13 activity was only 19%, which requires further interpretation considering the presence of sepsis. This case highlights the importance of early TMA diagnosis, ADAMTS13 blood testing before ECT, and the effectiveness of early plasmapherapy.
About the Authors
S. S. YarovenkoRussian Federation
Vladivostok
P. A. Knyazenko
Russian Federation
Pavel A. Knyazenko - Deputy Chief Physician for Anesthesiology and Intensive Care.
22 Sadovaya str., Vladivostok
I. A. Pavetiev
Russian Federation
Vladivostok
E. Yu. Minakova
Russian Federation
Vladivostok
V. A. Nevzorova
Russian Federation
Vladivostok
E. V. Markelova
Russian Federation
Vladivostok
References
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annan R, Bernard GR, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi: 10.1001/jama.2016.0287
2. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):1974–1982. doi: 10.1097/CCM.0000000000005357
3. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1–138. doi: 10.1038/kisup.2012.1
4. Tandukar S, Palevsky PM. Continuous Renal Replacement Therapy: Who, When, Why, and How. Chest. 2019;155(3):626–638. doi: 10.1016/j.chest.2018.09.004
5. Pène F, Russell L, Aubron C. Thrombocytopenia in the intensive care unit: diagnosis and management. Ann Intensive Care. 2025;15(1):25. doi: 10.1186/s13613-025-01447-x
6. Iba T, Levy JH, Wada H, Thachil J, Warkentin TE, Levi M. Subcommittee on Disseminated Intravascular Coagulation. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost. 2019;17(2):415–419. doi: 10.1111/jth.14354
7. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–666. doi: 10.1056/NEJMra1312353
8. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486–2495. doi: 10.1111/jth.15006
9. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496–2502. doi: 10.1111/jth.15010
10. Scully M, Rayment R, Clark A, Westwood JP, Cranfield T, Gooding R, et al. A British society for haematology guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br J Haematol. 2023;203(4):546–563. doi: 10.1111/bjh.19026
11. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the american society for apheresis: The eighth special issue. J Clin Apher. 2019;34(3):171–354. doi: 10.1002/jca.21705
12. Singh K, Kwong AC, Madarati H, Kunasekaran S, Sparring T, Fox-Robichaud AE, et al. Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients. PLoS One. 2021;16(2):e0247017. doi: 10.1371/journal.pone.0247017
13. Lin J-J, Chan O-W, Hsiao H-J, Wang Y, Hsia S-H, Chiu C-H. Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis. Medicine (Baltimore). 2016;95(16):e3374. doi: 10.1097/MD.0000000000003374
Review
For citations:
Yarovenko S.S., Knyazenko P.A., Pavetiev I.A., Minakova E.Yu., Nevzorova V.A., Markelova E.V. Multistep extracorporeal support strategy for community-acquired pneumonia complicated by sepsis and multiple organ failure (A clinical case). Pacific Medical Journal. 2026;(2):86-89. (In Russ.) https://doi.org/10.34215/1609-1175-2026-2-86-89
JATS XML





























